COVID-19 in Relation to Polypharmacy and Immunization (2020–2024)
Viruses · 2024
DOI: 10.3390/v16101533 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Anna Puigdellívol-Sánchez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medicina de Família, CAP Anton de Borja Centre Universitari, c/ Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa, 08191 Rubí, Spain. Hauptthemen laut MEDLINE: COVID-19, Polypharmacy, Hospitalization, SARS-CoV-2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Generalitat de Catalunya.
Themen: Medikationssicherheit
Abstract (Originalsprache)
Background
Observational studies reported worse COVID-19 evolution in relation to polypharmacy and reductions in COVID-19 hospital admissions and death in patients receiving chronic antihistamine treatment. The current profile of hospitalized patients with regard to different variants was analyzed to identify specific targets for future prospective trials.
Methods
COVID-19 admissions to the Hospital of Terrassa (11 March 2020–28 August 2024 (n = 1457), from the integral Consorci Sanitari de Terrassa population (n = 167,386 people) were studied. Age, gender, the number of chronic treatments (nT), and immunization status were analyzed.
Results
After 5 May 2023, 291 patients (54% females) required COVID hospitalization. Of these, 39% received >8 nT (23% receiving 5–7 nT), 70.2% were >70 years, and 93.4% survived. In total, 12% of patients admitted after 5 May 2024 were not vaccinated, while 59% received ≥4 vaccines (43% within the last 12 months). In total, 49% of admitted patients presented no previous infection (while 3% presented infection during the last year). Delta or Omicron variants would have accounted for ≥80% of admissions > 60 years compared to the first pandemic wave if no vaccines existed.
Conclusions
Patients > 70 years who receive ≥5 nT, without prior COVID-19 infections, should be the priority for prevention, with updated vaccination and early treatments to reduce hospitalizations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicina de Família, CAP Anton de Borja Centre Universitari, c/ Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa, 08191 Rubí, Spain.
- Laboratory of Surgical Neuroanatomy, Human Anatomy and Embryology Unit, Faculty of Medicine, Universitat de Barcelona, c/Casanova 143, 08036 Barcelona, Spain.
- Management, Control and Information Analysis Unit, Hospital Universitari de Terrassa, Consorci Sanitari de Terrassa, Carretera de Torrebonica s/n, 08227 Terrassa, Spain.
- Intelligence for Primary Care Research Group, Foundation University Institute for Primary Health Care Research Jordi Gol i Gurina, c/ Soler i March 6, 08242 Manresa, Spain.
- Unitat de Recerca i Innovació, Gerència d'Atenció Primària i a la Comunitat de la Catalunya Central, Institut Català de la Salut, c/ Soler i March 6, 08242 Manresa, Spain.
ORCID-Profile: Anna Puigdellívol-Sánchez, Marta Juanes-González, Roger Valls-Foix, Celia Lozano-Paz, Josep Vidal-Alaball
Förderung
- Generalitat de Catalunya
Zitieren
APA
Puigdellívol-Sánchez, A., Juanes-González, M., Calderón-Valdiviezo, A., Valls-Foix, R., González-Salvador, M., Lozano-Paz, C., & Vidal-Alaball, J. (2024). COVID-19 in Relation to Polypharmacy and Immunization (2020–2024). Viruses. https://doi.org/10.3390/v16101533
Vancouver
Puigdellívol-Sánchez A, Juanes-González M, Calderón-Valdiviezo A, Valls-Foix R, González-Salvador M, Lozano-Paz C, et al. COVID-19 in Relation to Polypharmacy and Immunization (2020–2024). Viruses. 2024. doi:10.3390/v16101533
BibTeX
@article{PuigdellvolSnchez2024,
author = {Puigdellívol-Sánchez, Anna and Juanes-González, Marta and Calderón-Valdiviezo, Ana and Valls-Foix, Roger and González-Salvador, Marta and Lozano-Paz, Celia and Vidal-Alaball, Josep},
title = {COVID-19 in Relation to Polypharmacy and Immunization (2020–2024)},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16101533}
}
EUVIMED